• Yue Chen, Xingyu Cheng, Chenyu Sun, Na Hyun Kim, Sujatha Kailas, Faisal Qureshi, Zeid Karadsheh, Yile Wu, Lei Hu, Zhen Zhou, Chandur Bhan, Keun Young Kim, Raveena Manem, Ce Cheng, and Qin Zhou.
• Department of Clinical Medicine, School of the First Clinical Medicine, Anhui Medical University, Hefei, Anhui, China.
• Postgrad Med J. 2022 Nov 1; 98 (1165): 866870866-870.

ObjectivesStudies on the association between metformin use and the risk of oesophageal cancer (OC) have generated controversial findings. This updated meta-analysis was conducted to reassess the effects of metformin on OC.MethodsA comprehensive search strategy was conducted to select relevant studies from origination to February 2021. Heterogeneity was evaluated through the Q test and I2 statistics. HRs and 95% CIs were pooled through either random-effect or fixed-effect models. Meta-regression, subgroup analyses, sensitivity analysis and publication bias diagnosis were also performed.ResultsSeven studies with 5 426 343 subjects were included. Metformin use was associated with reduced risk of OC (HR=0.69, 95% CI 0.54 to 0.87, p<0.001). Sensitivity analysis suggested that the results were relatively stable.ConclusionMetformin is associated with a reduced risk of OC. More well-designed studies are still needed to further elaborate on these associations.Prospero Registration NumberCRD42021237127.© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

11 keywords...

hide…